This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Illei, P. B. Articles by Ladanyi, M. Search for Related Content PubMed PubMed Citation Articles by Illei, P. B. Articles by Ladanyi, M.

Homozygous Deletion of CDKN2A and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas

Departments of Pathology [P. B. I., M. F. Z., M. L.] and Surgery [V. W. R.], Memorial Sloan-Kettering Cancer Center, New York, New York, 10021

Purpose: Homozygous deletions at chromosome region 9p21 targeting the CDKN2A gene have been reported as a common cytogenetic abnormality in mesothelioma. MTAP, a gene 100-kb telomeric to CDKN2A, encodes methylthioadenosine phosphorylase, an enzyme essential in the salvage of cellular adenine and methionine, and its codeletion with CDKN2A has been reported in other tumors. The aim of this study was to define the prevalence of homozygous deletion of CDKN2A alone or in combination with MTAP in a large series of pleural mesothelioma.

Experimental Design: We used a fluorescent in situ hybridization assay for CDKN2A and MTAP on interphase nuclei in imprints of frozen tissue from 95 cases of pleural mesothelioma. Histologically, the cases were classified as epithelial (71), biphasic (19) and sarcomatous (5). In each experiment, a 9p21 locus specific probe and a chromosome 9 centromeric probe were used and fluorescent in situ hybridization signals for both probes were simultaneously recorded in at least 100 nuclei. Cases were considered homozygously deleted if both 9p21 signals were lost in at least 20% of nuclei.

Results: Overall, 70 cases (74%) had homozygous deletion of CDKN2A. MTAP was codeleted in 64 of these cases (91%). No case with MTAP deletion without CDKN2A deletion was identified. Homozygous loss of CDKN2A was seen in 49 of 71 epithelial (70%), 16 of 19 biphasic (89%), and 5 of 5 sarcomatous (100%) mesotheliomas.

Conclusions: Homozygous deletion of CDKN2A is seen in the majority of pleural mesotheliomas, and MTAP is codeleted in most of these cases. Previous cell line studies have shown that loss of MTAP renders cells dependent on de novo synthesis of purine derivatives. Thus, the particularly high prevalence of MTAP codeletion in mesothelioma makes it an ideal candidate for trials of targeted therapy using inhibitors of de novo AMP synthesis (e.g., L-alanosine).

This article has been cited by other articles:

				S. Chattopadhyay, R. Zhao, E. Tsai, V. L. Schramm, and I. D. Goldman The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Mol. Cancer Ther., October 1, 2006; 5(10): 2549 - 2555. [Abstract] [Full Text] [PDF]

				A. J. Holloway, D. S. Diyagama, K. Opeskin, J. Creaney, B. W.S. Robinson, R. A. Lake, and D. D.L. Bowtell A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions Clin. Cancer Res., September 1, 2006; 12(17): 5129 - 5135. [Abstract] [Full Text] [PDF]

				S. Marce, O. Balague, L. Colomo, A. Martinez, S. Holler, N. Villamor, F. Bosch, G. Ott, A. Rosenwald, L. Leoni, et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin. Cancer Res., June 15, 2006; 12(12): 3754 - 3761. [Abstract] [Full Text] [PDF]

				F. Lopez-Rios, S. Chuai, R. Flores, S. Shimizu, T. Ohno, K. Wakahara, P. B. Illei, S. Hussain, L. Krug, M. F. Zakowski, et al. Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Res., March 15, 2006; 66(6): 2970 - 2979. [Abstract] [Full Text] [PDF]

				A. Batova, H. Cottam, J. Yu, M. B. Diccianni, C. J. Carrera, and A. L. Yu EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine Blood, February 1, 2006; 107(3): 898 - 903. [Abstract] [Full Text] [PDF]

				C. A. Karikari, M. Mullendore, J. R. Eshleman, P. Argani, L. M. Leoni, S. Chattopadhyay, M. Hidalgo, and A. Maitra Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers Mol. Cancer Ther., December 1, 2005; 4(12): 1860 - 1866. [Abstract] [Full Text] [PDF]

				A. C. Borczuk, R. N. Taub, M. Hesdorffer, H. Hibshoosh, J. A. Chabot, M. L. Keohan, R. Alsberry, D. Alexis, and C. A. Powell P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma Clin. Cancer Res., May 1, 2005; 11(9): 3303 - 3308. [Abstract] [Full Text] [PDF]

				H.-Y. Huang, P. B. Illei, Z. Zhao, M. Mazumdar, A. G. Huvos, J. H. Healey, L. H. Wexler, R. Gorlick, P. Meyers, and M. Ladanyi Ewing Sarcomas With p53 Mutation or p16/p14ARF Homozygous Deletion: A Highly Lethal Subset Associated With Poor Chemoresponse J. Clin. Oncol., January 20, 2005; 23(3): 548 - 558. [Abstract] [Full Text] [PDF]